Prelude Therapeutics Inc (NASDAQ: PRLD) kicked off on Monday, up 150.31% from the previous trading day, before settling in for the closing price of $1.59. Over the past 52 weeks, PRLD has traded in a range of $0.61-$1.91.
During the last 5-year period, the sales drop of Healthcare Sector giant was -21.61%. While this was happening, its average annual earnings per share was recorded 17.86%. With a float of $24.45 million, this company’s outstanding shares have now reached $43.74 million.
Prelude Therapeutics Inc (PRLD) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Prelude Therapeutics Inc is 56.80%, while institutional ownership is 28.73%. The most recent insider transaction that took place on Mar 25 ’25, was worth 69,250. In this transaction Chief Chemistry Officer of this company bought 100,000 shares at a rate of $0.69, taking the stock ownership to the 480,123 shares. Before that another transaction happened on Mar 25 ’25, when Company’s CEO bought 675,000 for $0.69, making the entire transaction worth $467,438. This insider now owns 1,999,296 shares in total.
Prelude Therapeutics Inc (PRLD) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.43 earnings per share (EPS), higher than consensus estimate (set at -0.46) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 17.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.45% during the next five years compared to -21.61% drop over the previous five years of trading.
Prelude Therapeutics Inc (NASDAQ: PRLD) Trading Performance Indicators
Take a look at Prelude Therapeutics Inc’s (PRLD) current performance indicators. Last quarter, stock had a quick ratio of 3.68. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 32.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.78, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -0.95 in one year’s time.
Technical Analysis of Prelude Therapeutics Inc (PRLD)
Looking closely at Prelude Therapeutics Inc (NASDAQ: PRLD), its last 5-days average volume was 7.02 million, which is a jump from its year-to-date volume of 0.37 million. As of the previous 9 days, the stock’s Stochastic %D was 79.36%.
During the past 100 days, Prelude Therapeutics Inc’s (PRLD) raw stochastic average was set at 93.08%, which indicates a significant increase from 92.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.3600 in the past 14 days, which was higher than the 0.1500 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3700, while its 200-day Moving Average is $1.0000. However, in the short run, Prelude Therapeutics Inc’s stock first resistance to watch stands at $4.9900. Second resistance stands at $6.0000. The third major resistance level sits at $7.7800. If the price goes on to break the first support level at $2.2000, it is likely to go to the next support level at $0.4200.
Prelude Therapeutics Inc (NASDAQ: PRLD) Key Stats
The company with the Market Capitalisation of 225.23 million has total of 56,600K Shares Outstanding. Its annual sales at the moment are 7,000 K in contrast with the sum of -127,170 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -32,090 K.
